Full text is available at the source.
Combination therapy with PD-1 or PD-L1 inhibitors for cancer
Using PD-1 or PD-L1 blockers together as cancer treatment
AI simplified
Abstract
Combinations of chemotherapy and PD-1/PD-L1 inhibitors are now used in clinical practice for treating advanced non-small cell lung cancer and small cell lung cancer.
- Only a limited number of patients benefit from immune checkpoint inhibitor (ICI) therapy for cancer.
- Preclinical studies indicate that combining PD-1/PD-L1 inhibitors with chemotherapy or CTLA-4 antibodies may improve treatment outcomes for advanced cancer.
- Combination therapies, such as ipilimumab with nivolumab, have shown survival benefits in patients with melanoma or renal cell carcinoma.
- Ongoing clinical trials are exploring ICI combination therapy against standard treatments for various tumor types.
- Identifying patients who will benefit from PD-1/PD-L1 inhibitor monotherapy is challenging and requires new biomarkers.
- Further investigation into the immune-related adverse events of ICI combination therapy is necessary to develop effective management strategies.
AI simplified